Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App




AI Tool Predicts Immunotherapy Response Using Tumor Senescence Signals

By LabMedica International staff writers
Posted on 22 Oct 2026

Patients receiving the same cancer immunotherapy can have markedly different outcomes, with some showing little or no response. More...

Identifying these patients earlier could reduce the costs of ineffective treatment and delays in alternative therapy. Differences in the tumor microenvironment, including senescent cells that suppress immune-cell activity, may help explain this variability. Building on this connection, researchers have developed an artificial intelligence method that accounts for tumor cell senescence to predict immunotherapy response.

POSTECH (Pohang University of Science and Technology; Pohang, South Korea) developed a machine-learning method that analyzes genetic information from cancer patients to predict response to immunotherapy. The technology uses a stepwise prediction framework rather than processing all genetic information at once. It first identifies tumors with a senescent microenvironment in which immune-cell activity is suppressed, then progressively stratifies patients as likely responders or nonresponders.

The approach was designed to address a key limitation in artificial intelligence-based prediction: the small number of available patient samples compared with the large volume of genetic information. According to the researchers, this imbalance can cause models to become overly tailored to training data and perform poorly in new patients. The step-by-step method was intended to reduce bias toward any single patient group and support more robust performance across diverse populations.

In experiments, the method outperformed biomarkers currently used in clinical practice for predicting treatment response across four cancer types, including skin cancer, and six patient cohorts. It also showed consistent performance compared with other existing prediction methods when validated in an independent skin cancer cohort that had not been included in model training. The study, titled “Senescence-aware filtering facilitates robust prediction of cancer immunotherapy outcomes,” was published in npj Digital Medicine.

The findings highlight the role of a senescent tumor microenvironment in predicting immunotherapy outcomes. The researchers stated that identifying whether senescent cells may interfere with immunotherapy could support more individualized treatment strategies. The work was conducted at POSTECH.

“By taking cellular senescence into account, this prediction method could help more cancer patients benefit from immunotherapy in the future. Through follow-up studies, we will continue to develop AI-based approaches for predicting treatment response that more precisely reflect the tumor microenvironment,” said Sanguk Kim, professor in the Department of Life Sciences and the Graduate School of Convergence Science and Technology at POSTECH.

Related Links
POSTECH


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
Fully Automated Urinalysis System
DxU 1800 Fully Automated Urinalysis System
Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Researchers combined a blood-based biomarker of Alzheimer’s disease with age, sex, and genetic risk to estimate future cognitive impairment risk in asymptomatic adults (Image Credit: Adobe Stock)

Blood Biomarker Model May Help Estimate Five- and 10-Year Cognitive Impairment Risk

Estimating future cognitive impairment risk remains challenging in cognitively healthy adults, particularly when biomarker findings are reduced to simple positive or negative results. Because mild cognitive... Read more

Immunology

view channel
Image: The panel expands Cepheid’s respiratory testing portfolio on the GeneXpert platform, offering laboratories greater flexibility in selecting tests based on clinical needs. (Photo courtesy of Cepheid)

Multiplex PCR Test Gains CE Marking to Support Respiratory Infection Diagnosis

Acute respiratory infections often present with overlapping symptoms, making it difficult to distinguish between viral and bacterial causes. Seasonal surges of influenza-like illness in Europe further... Read more

Microbiology

view channel
Image: Malaria is caused by Plasmodium parasites, primarily transmitted through the bites of infected female Anopheles mosquitoes (Image Credit: Adobe Stock)

Complete Malaria Genomes Could Improve Species Identification and Surveillance

Malaria remains a major global health challenge, with an estimated 282 million cases and 610,000 deaths worldwide in 2024. Although most research has focused on Plasmodium falciparum, Plasmodium ovale... Read more

Industry

view channel
Image: The TOMR trial uses Signatera-guided MRD testing to identify high-risk patients for curative-intent treatment.

Natera and Incyte Collaborate on MRD-Guided Colorectal Cancer Treatment Study

Natera (Austin, TX, USA) has entered into a clinical collaboration with Incyte (Wilmington, DE, USA) for a Phase II study evaluating molecular residual disease (MRD)-guided treatment in colorectal cancer.... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.